Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
SAB Biotherapeutics, Inc. SABS
$0.91
-$0.03 (-3.84%)
На 18:04, 12 мая 2023
+229.67%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
45610009.00000000
-
week52high
2.31
-
week52low
0.37
-
Revenue
23904181
-
P/E TTM
-6
-
Beta
1.26379700
-
EPS
-0.42000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Chardan Capital | Buy | Buy | 11 авг 2022 г. |
| Chardan Capital | Buy | Buy | 13 мая 2022 г. |
| Chardan Capital | Buy | Buy | 01 апр 2022 г. |
| Chardan Capital | Buy | 05 ноя 2021 г. | |
| Baird | Outperform | 02 ноя 2021 г. | |
| HC Wainwright & Co. | Buy | 29 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| HAMILTON CHRISTINE E | A | 82987 | 82987 | 07 дек 2022 г. |
| HAMILTON CHRISTINE E | A | 3111334 | 82987 | 07 дек 2022 г. |
| Link David Charles | A | 41493 | 41493 | 07 дек 2022 г. |
| Link David Charles | A | 57313 | 41493 | 07 дек 2022 г. |
| Spragens Jeffrey G | A | 82987 | 82987 | 07 дек 2022 г. |
| Spragens Jeffrey G | A | 394989 | 82987 | 07 дек 2022 г. |
| Sullivan Eddie Joe | A | 35000 | 35000 | 13 сент 2022 г. |
| Reich Samuel J | A | 525000 | 525000 | 13 сент 2022 г. |
| Kropotova Alexandra | A | 18325 | 18325 | 13 сент 2022 г. |
| Giberson Scott | A | 25000 | 25000 | 13 сент 2022 г. |
Новостная лента
SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco
GlobeNewsWire
15 дек 2022 г. в 08:30
SIOUX FALLS, S.D., Dec. 15, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for human donors, announced today that SAB Biotherapeutics has been selected to present at the Biotech Showcase 2023 meeting, an investor conference that drives biotech innovation and global collaboration through presentations delivered by innovative biotech companies, face-to-face networking and one-to-one meetings. The conference is taking place Jan. 9-11 in San Francisco, in parallel with the J.P. Morgan 41st Annual Health Care Conference.
SAB (SABS) Abandons COVID-19 Treatment Study, Stock Plummets
Zacks Investment Research
03 мар 2022 г. в 19:10
Low hospitalization rates force SAB Biotherapeutics (SABS) to discontinue the late-stage study that is evaluating its COVID-19 antibody treatment. Stock down almost 40% post the announcement.
SAB Biotherapeutics (SABS) Posts Data From COVID Treatment Study
Zacks Investment Research
26 янв 2022 г. в 09:14
Following positive data from phase II study, SAB Biotherapeutics (SABS) starts a phase III study evaluating its COVID antibody treatment.
On Positive Virology Data, SAB Biotherapeutics' COVID-19 Drug To Move To Phase 3 In NIH ACTIV-2 Trial
Benzinga
24 янв 2022 г. в 09:26
SAB Biotherapeutics Inc (NASDAQ: SABS) has reported positive Phase 2 safety and efficacy data demonstrating that SAB-185 met the criteria required to move to Phase 3 in the National Institutes of Health (NIH) COVID-19 ACTIV-2 Trial. SAB-185 is a fully human, specifically targeted, broadly neutralizing polyclonal antibody candidate for high-risk non-hospitalized patients with mild to moderate COVID-19.
FDA Lab Testing Confirms SAB Biotherapeutics' COVID-19 Antibody Neutralizes Omicron Variant
Benzinga
16 дек 2021 г. в 08:06
SAB Biotherapeutics Inc (NASDAQ: SABS) announced that SAB-185, its COVID-19 therapeutic candidate, retains neutralization activity against the omicron variant in an in vitro pseudovirus model. The results indicate that SAB-185 retains a potent ability to neutralize recombinant S protein lentiviral pseudovirus that mimics the SARS-CoV-2 Omicron (B.1.1.529) variant.